Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines

Inclusion Criteria: * Moderate or severe glabellar frown lines * Female or male, 30 to 65 years of age in good general health * Women of childbearing potential must agree to use an effective method of birth control during the course of the study * Willing to refrain from receipt of facial fillers, laser treatments or use of products that affect skin remodeling and causes an active dermal response Exclusion Criteria: * Any neurological condition that may place the subject at increased risk with exposure to Botulinum Toxin Type A such as amyotrophic lateral sclerosis and motor neuropathy, Lambert-Eaton syndrome, and myasthenia gravis * Muscle weakness or paralysis, particularly in the treatment area * Active skin disease or infections or irritation at the treatment area * Facial asymmetry, deep dermal scarring, or inability to substantially lessen the glabellar frown lines by manually spreading them apart * Treatment with Botulinum Toxin Type A in the face in the last 6 months or in the last 3 months anywhere in the body